Promoters held 74.12 per cent stake in the company as of 31-Dec-2022, while FIIs owned 3.97 per cent, DIIs 0.06 per cent.

EBITDA margins are expected to improve by 156 bps to 19.9%. Net profit is expected to increase 11.66% QoQ to Rs 21 crore.

Shalby is among the largest chains of multispecialty hospitals and tertiary care centers in the country today. Currently, Shalby Hospitals ...

Shalby Ltd. key Products/Revenue Segments include Sale of services, Medicines and Other Operating Revenue for the year ending 31-Mar-2022.

“Within the hospital space, Shalby Hospitals has the largest capacity of close to 2,000 beds. Despite occupancies of less than 50%, they ha...

The company is currently valued at Rs 1,700 crore, much of which has come during the last one year, as the stock gained 155 per cent. In fa...

Shalby Ltd., incorporated in the year 2004, is a Small Cap company (having a market cap of Rs 989.91 Crore) operating in Hospitals & Allied...

Shalby has a debt free balance sheet, a unique feature among hospital chains, which are on expansion mode.

In the Nifty pack, 39 stocks were in the green, while 11 stocks were in the red.

Dr Lal Pathlabs, Bayer Cropscience and Tata Chemicals are some of the companies which will report their December quarter earnings today.

The Nifty50 index closed 13 points down at 10,477, while the BSE Sensex ended Thursday's session 64 points down at 33,848.

Equity benchmarks Nifty50 and Sensex remained cautious ahead of futures and options (F&O) expiry for December, due today.

PSU bank stocks were the only losers in the trade. Nifty PSU Bank index lost 7 points or 0.20%.

Both indices wiped off some of their gains after hitting their highest level in early trade.

Dr Shah, claims that Shalby owes him medical consultancy fees of about Rs 41 lakh.

Here's a quick roundup of top stocks and sectors that made headlines in today's session.

The hospital sector has not been rewarding for investors for the past one year.